Ignite Creation Date:
2025-12-25 @ 1:20 AM
Ignite Modification Date:
2026-01-01 @ 9:03 PM
Study NCT ID:
NCT06008093
Status:
RECRUITING
Last Update Posted:
2025-10-27
First Post:
2023-08-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
Sponsor:
AstraZeneca
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-04-04
Start Date Type:
ACTUAL
Primary Completion Date:
2027-08-17
Primary Completion Date Type:
ESTIMATED
Completion Date:
2031-03-20
Completion Date Type:
ESTIMATED
First Submit Date:
2023-08-17
First Submit QC Date:
None
Study First Post Date:
2023-08-23
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-24
Last Update Post Date:
2025-10-27
Last Update Post Date Type:
ESTIMATED